종양-암 치료제 시장 : 약물 종류별, 적응증별 - 세계 기회 분석 및 산업 예측(2024-2033년)

Oncology-Cancer Drugs Market By Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy , Hormonal Therapy), By Indication : Global Opportunity Analysis and Industry Forecast, 2024-2033

US $ 4,425 ￦ 6,071,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 7,412 ￦ 10,170,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

세계 종양-암 치료제 시장은 2023년 1,670억 달러로 평가되며, 2024-2033년 연평균 7.2% 성장하여 2033년에는 3,352억 달러에 달할 것으로 예상됩니다.

종양-암 치료제에는 다양한 종류의 암 진단, 치료 및 관리에 특화된 의약품이 포함됩니다. 이러한 의약품은 암세포를 표적으로 삼거나 암의 성장과 전이에 관여하는 과정을 억제합니다. 전통적인 화학요법부터 면역요법, 정밀의료와 같은 표적치료제까지 다양한 치료약물 접근방식이 포함됩니다.

세계 종양-암 치료제 시장은 고령화, 생활습관 변화, 환경적 노출에 따른 전 세계 암 발병률 증가로 인해 혁신적인 치료법에 대한 수요가 증가하고 있습니다. 이러한 환자 수의 증가는 다양한 암종과 미충족 의료 수요를 충족시키기 위한 지속적인 연구 개발 노력의 필요성을 강조하고 있습니다. 또한, 분자생물학, 유전체 과학, 면역요법 등 과학 기술 분야의 발전은 항암제 개발의 큰 진전을 이끌고 있습니다. 암의 진행을 촉진하는 특정 분자 이상에 초점을 맞춘 정밀의료 전략의 부상은 점점 더 두드러지고 있습니다. 그 결과 더 강력하고 덜 해로운 치료법이 개발되어 종양-암 치료제 시장의 성장에 박차를 가하고 있습니다.

그러나 종양-암 치료제의 개발에는 많은 비용이 소요되고, 전임상, 임상시험, 규제 당국의 승인에 많은 투자가 필요하기 때문에 종양-암 치료제의 채택은 제한적입니다. 그럼에도 불구하고, 새로운 치료법 및 약물 관련 규제 당국의 승인은 시장 진입 기업에게 몇 가지 기회를 제공할 것으로 예상됩니다. 예를 들어, 2023년 10월 미국 식품의약국(FDA)은 여름에 다양한 암에 대한 몇 가지 새로운 치료법을 승인했고, 7월에는 자궁내막암에 대한 Jemperli(dostarlimab)의 새로운 적응증인 자궁내막암에 대한 새로운 적응증을 승인했습니다.

세분화 개요

종양-암 치료제 시장은 약제군별, 적응증별, 지역별로 구분됩니다. 약제 클래스별로는 화학요법, 표적치료제, 면역요법(생물학적 제제), 호르몬요법으로 분류됩니다. 적응증별로는 폐암, 위암, 대장암, 유방암, 전립선암, 간암, 식도암, 자궁경부암, 신장암, 방광암, 기타 암으로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 나누어 분석합니다.

주요 조사 결과

약물 종류별로는 표적치료제 부문이 2023년 가장 큰 시장 점유율을 차지했습니다.

적응증별로는 유방암 부문이 2023년 시장에서 가장 높은 점유율을 차지했습니다.

지역별로는 북미가 2023년 종양-암 치료제 시장을 장악했습니다.

경쟁 시나리오

이 보고서는 사용자 정의가 가능합니다.

• 규제 가이드라인
• 고객의 관심사에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 개요 확대 목록
• 과거 시장 데이터
• 주요 진입기업 세부 정보(위치, 연락처, 공급업체/벤더 네트워크 등 포함, 엑셀 형식)

목차

제1장 소개

제2장 주요 요약

제3장 시장 상황

• 시장 정의와 범위
• 주요 조사 결과
  • 주요 투자 기회
  • 주요 성공 전략
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 종양-암 치료제 시장 : 약물 종류별

• 시장 개요
• 화학요법
• 표적요법
• 면역요법(생물학적 요법)
• 호르몬요법

제5장 종양-암 치료제 시장 : 적응증별

• 시장 개요
• 폐암
• 위암
• 대장암
• 유방암
• 전립선암
• 간암
• 식도암
• 자궁경부암
• 신장암
• 방광암
• 기타 암

제6장 종양-암 치료제 시장 : 지역별

• 시장 개요
• 북미
  • 주요 시장 동향과 기회
  • 미국의 종양-암 치료제 시장
  • 캐나다의 종양-암 치료제 시장
  • 멕시코의 종양-암 치료제 시장
• 유럽
  • 주요 시장 동향과 기회
  • 독일의 종양-암 치료제 시장
  • 프랑스의 종양-암 치료제 시장
  • 영국의 종양-암 치료제 시장
  • 이탈리아의 종양-암 치료제 시장
  • 스페인의 종양-암 치료제 시장
  • 기타 유럽의 종양-암 치료제 시장
• 아시아태평양
  • 주요 시장 동향과 기회
  • 중국의 종양-암 치료제 시장
  • 일본의 종양-암 치료제 시장
  • 인도의 종양-암 치료제 시장
  • 호주 종양-암 치료제 시장
  • 한국의 종양-암 치료제 시장
  • 기타 아시아태평양의 종양-암 치료제 시장
• 라틴아메리카, 중동 및 아프리카
  • 주요 시장 동향과 기회
  • 브라질의 종양-암 치료제 시장
  • 남아프리카공화국의 종양-암 치료제 시장
  • 사우디아라비아의 종양-암 치료제 시장
  • 기타 라틴아메리카, 중동 및 아프리카 종양-암 치료제 시장

제7장 경쟁 상황

• 소개
• 주요 성공 전략
• 주요 10개사 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제8장 기업 개요

• AbbVie Inc.
• Amgen
• Astellas Pharma Inc.
• AstraZeneca Plc
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Johnson And Johnson
• Merck And Co., Inc.
• Novartis AG
• Pfizer Inc.

ksm

영문 목차

영문목차

The global oncology-cancer drugs market was valued at $167.0 billion in 2023, and is projected to reach $335.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

The oncology/cancer drugs encompass pharmaceuticals specifically designed to diagnose, treat, and manage various types of cancer. These drugs target cancerous cells or interfere with processes involved in cancer growth and spread. It includes a wide array of therapeutic approaches, ranging from traditional chemotherapy to more targeted therapies like immunotherapy and precision medicine.

The global oncology-cancer drugs market is driven by rise in incidence of cancer globally due to aging population, lifestyle changes, and environmental exposures, which drives the demand for innovative therapies. This growing patient population highlights the need for continuous R&D efforts to address diverse cancer types and unmet medical needs. Furthermore, progress in the field of science and technology, specifically in disciplines such as molecular biology, genomics, and immunotherapy, are propelling substantial advancements in the development of cancer drugs. The rise of precision medicine strategies, which focus on specific molecular abnormalities that fuel cancer progression, is becoming increasingly prominent. This has resulted in the creation of more potent and less harmful therapies, fueling growth in the oncology drugs market.

However, high development costs of oncology drugs are extensive and costly, often requiring significant investments in preclinical studies, clinical trials, and regulatory approvals which limit the adoption of cancer drugs. Nevertheless, approval from regulatory authorities associated with new treatments and drugs is expected to create several opportunities for the market players. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved several new treatments for a range of cancers over the summer. In July, the FDA approved a new indication for Jemperli (dostarlimab) in endometrial cancer.

Segmentation Overview

The oncology-cancer drugs market is segmented into drug class type, indication, and region. Depending on drug class type, the market is categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. According to indication, it is divided into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

Depending on drug class type, the targeted therapy segment held the largest market share in 2023.

By indication, the breast cancer segment accounted for the highest share in the market in 2023.

Region wise, North America dominated the oncology-cancer drugs market in 2023.

Competitive Scenario

The major players operating in the oncology/cancer drugs market include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. Other players in oncology/cancer drugs market includes Bayer AG, Regeneron Pharmaceuticals Inc., and Eli Lilly and Company. These players have adopted several strategies, including partnerships, collaborations, and R&D to maintain their position in the competitive market.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

• Chemotherapy
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy

By Indication

• Lung Cancer
• Stomach Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Liver Cancer
• Esophagus Cancer
• Cervical Cancer
• Kidney Cancer
• Bladder Cancer
• Other Cancers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players:

• AbbVie Inc.
• Amgen
• Astellas Pharma Inc.
• AstraZeneca plc
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report Description
• 1.2. Key Market Segments
• 1.3. Key Benefits
• 1.4. Research Methodology
  • 1.4.1. Primary Research
  • 1.4.2. Secondary Research
  • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

• 3.1. Market Definition and Scope
• 3.2. Key Findings
  • 3.2.1. Top Investment Pockets
  • 3.2.2. Top Winning Strategies
• 3.3. Porter's Five Forces Analysis
  • 3.3.1. Bargaining Power of Suppliers
  • 3.3.2. Threat of New Entrants
  • 3.3.3. Threat of Substitutes
  • 3.3.4. Competitive Rivalry
  • 3.3.5. Bargaining Power among Buyers
• 3.4. Market Dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS

• 4.1. Market Overview
  • 4.1.1 Market Size and Forecast, By Drug Class
• 4.2. Chemotherapy
  • 4.2.1. Key Market Trends, Growth Factors and Opportunities
  • 4.2.2. Market Size and Forecast, By Region
  • 4.2.3. Market Share Analysis, By Country
• 4.3. Targeted Therapy
  • 4.3.1. Key Market Trends, Growth Factors and Opportunities
  • 4.3.2. Market Size and Forecast, By Region
  • 4.3.3. Market Share Analysis, By Country
• 4.4. Immunotherapy (Biologic Therapy)
  • 4.4.1. Key Market Trends, Growth Factors and Opportunities
  • 4.4.2. Market Size and Forecast, By Region
  • 4.4.3. Market Share Analysis, By Country
• 4.5. Hormonal Therapy
  • 4.5.1. Key Market Trends, Growth Factors and Opportunities
  • 4.5.2. Market Size and Forecast, By Region
  • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION

• 5.1. Market Overview
  • 5.1.1 Market Size and Forecast, By Indication
• 5.2. Lung Cancer
  • 5.2.1. Key Market Trends, Growth Factors and Opportunities
  • 5.2.2. Market Size and Forecast, By Region
  • 5.2.3. Market Share Analysis, By Country
• 5.3. Stomach Cancer
  • 5.3.1. Key Market Trends, Growth Factors and Opportunities
  • 5.3.2. Market Size and Forecast, By Region
  • 5.3.3. Market Share Analysis, By Country
• 5.4. Colorectal Cancer
  • 5.4.1. Key Market Trends, Growth Factors and Opportunities
  • 5.4.2. Market Size and Forecast, By Region
  • 5.4.3. Market Share Analysis, By Country
• 5.5. Breast Cancer
  • 5.5.1. Key Market Trends, Growth Factors and Opportunities
  • 5.5.2. Market Size and Forecast, By Region
  • 5.5.3. Market Share Analysis, By Country
• 5.6. Prostate Cancer
  • 5.6.1. Key Market Trends, Growth Factors and Opportunities
  • 5.6.2. Market Size and Forecast, By Region
  • 5.6.3. Market Share Analysis, By Country
• 5.7. Liver Cancer
  • 5.7.1. Key Market Trends, Growth Factors and Opportunities
  • 5.7.2. Market Size and Forecast, By Region
  • 5.7.3. Market Share Analysis, By Country
• 5.8. Esophagus Cancer
  • 5.8.1. Key Market Trends, Growth Factors and Opportunities
  • 5.8.2. Market Size and Forecast, By Region
  • 5.8.3. Market Share Analysis, By Country
• 5.9. Cervical Cancer
  • 5.9.1. Key Market Trends, Growth Factors and Opportunities
  • 5.9.2. Market Size and Forecast, By Region
  • 5.9.3. Market Share Analysis, By Country
• 5.10. Kidney Cancer
  • 5.10.1. Key Market Trends, Growth Factors and Opportunities
  • 5.10.2. Market Size and Forecast, By Region
  • 5.10.3. Market Share Analysis, By Country
• 5.11. Bladder Cancer
  • 5.11.1. Key Market Trends, Growth Factors and Opportunities
  • 5.11.2. Market Size and Forecast, By Region
  • 5.11.3. Market Share Analysis, By Country
• 5.12. Other Cancers
  • 5.12.1. Key Market Trends, Growth Factors and Opportunities
  • 5.12.2. Market Size and Forecast, By Region
  • 5.12.3. Market Share Analysis, By Country

CHAPTER 6: ONCOLOGY-CANCER DRUGS MARKET, BY REGION

• 6.1. Market Overview
  • 6.1.1 Market Size and Forecast, By Region
• 6.2. North America
  • 6.2.1. Key Market Trends and Opportunities
  • 6.2.2. Market Size and Forecast, By Drug Class
  • 6.2.3. Market Size and Forecast, By Indication
  • 6.2.4. Market Size and Forecast, By Country
  • 6.2.5. U.S. Oncology-Cancer Drugs Market
    • 6.2.5.1. Market Size and Forecast, By Drug Class
    • 6.2.5.2. Market Size and Forecast, By Indication
  • 6.2.6. Canada Oncology-Cancer Drugs Market
    • 6.2.6.1. Market Size and Forecast, By Drug Class
    • 6.2.6.2. Market Size and Forecast, By Indication
  • 6.2.7. Mexico Oncology-Cancer Drugs Market
    • 6.2.7.1. Market Size and Forecast, By Drug Class
    • 6.2.7.2. Market Size and Forecast, By Indication
• 6.3. Europe
  • 6.3.1. Key Market Trends and Opportunities
  • 6.3.2. Market Size and Forecast, By Drug Class
  • 6.3.3. Market Size and Forecast, By Indication
  • 6.3.4. Market Size and Forecast, By Country
  • 6.3.5. Germany Oncology-Cancer Drugs Market
    • 6.3.5.1. Market Size and Forecast, By Drug Class
    • 6.3.5.2. Market Size and Forecast, By Indication
  • 6.3.6. France Oncology-Cancer Drugs Market
    • 6.3.6.1. Market Size and Forecast, By Drug Class
    • 6.3.6.2. Market Size and Forecast, By Indication
  • 6.3.7. UK Oncology-Cancer Drugs Market
    • 6.3.7.1. Market Size and Forecast, By Drug Class
    • 6.3.7.2. Market Size and Forecast, By Indication
  • 6.3.8. Italy Oncology-Cancer Drugs Market
    • 6.3.8.1. Market Size and Forecast, By Drug Class
    • 6.3.8.2. Market Size and Forecast, By Indication
  • 6.3.9. Spain Oncology-Cancer Drugs Market
    • 6.3.9.1. Market Size and Forecast, By Drug Class
    • 6.3.9.2. Market Size and Forecast, By Indication
  • 6.3.10. Rest of Europe Oncology-Cancer Drugs Market
    • 6.3.10.1. Market Size and Forecast, By Drug Class
    • 6.3.10.2. Market Size and Forecast, By Indication
• 6.4. Asia-Pacific
  • 6.4.1. Key Market Trends and Opportunities
  • 6.4.2. Market Size and Forecast, By Drug Class
  • 6.4.3. Market Size and Forecast, By Indication
  • 6.4.4. Market Size and Forecast, By Country
  • 6.4.5. China Oncology-Cancer Drugs Market
    • 6.4.5.1. Market Size and Forecast, By Drug Class
    • 6.4.5.2. Market Size and Forecast, By Indication
  • 6.4.6. Japan Oncology-Cancer Drugs Market
    • 6.4.6.1. Market Size and Forecast, By Drug Class
    • 6.4.6.2. Market Size and Forecast, By Indication
  • 6.4.7. India Oncology-Cancer Drugs Market
    • 6.4.7.1. Market Size and Forecast, By Drug Class
    • 6.4.7.2. Market Size and Forecast, By Indication
  • 6.4.8. Australia Oncology-Cancer Drugs Market
    • 6.4.8.1. Market Size and Forecast, By Drug Class
    • 6.4.8.2. Market Size and Forecast, By Indication
  • 6.4.9. South Korea Oncology-Cancer Drugs Market
    • 6.4.9.1. Market Size and Forecast, By Drug Class
    • 6.4.9.2. Market Size and Forecast, By Indication
  • 6.4.10. Rest of Asia-Pacific Oncology-Cancer Drugs Market
    • 6.4.10.1. Market Size and Forecast, By Drug Class
    • 6.4.10.2. Market Size and Forecast, By Indication
• 6.5. LAMEA
  • 6.5.1. Key Market Trends and Opportunities
  • 6.5.2. Market Size and Forecast, By Drug Class
  • 6.5.3. Market Size and Forecast, By Indication
  • 6.5.4. Market Size and Forecast, By Country
  • 6.5.5. Brazil Oncology-Cancer Drugs Market
    • 6.5.5.1. Market Size and Forecast, By Drug Class
    • 6.5.5.2. Market Size and Forecast, By Indication
  • 6.5.6. South Africa Oncology-Cancer Drugs Market
    • 6.5.6.1. Market Size and Forecast, By Drug Class
    • 6.5.6.2. Market Size and Forecast, By Indication
  • 6.5.7. Saudi Arabia Oncology-Cancer Drugs Market
    • 6.5.7.1. Market Size and Forecast, By Drug Class
    • 6.5.7.2. Market Size and Forecast, By Indication
  • 6.5.8. Rest of LAMEA Oncology-Cancer Drugs Market
    • 6.5.8.1. Market Size and Forecast, By Drug Class
    • 6.5.8.2. Market Size and Forecast, By Indication

CHAPTER 7: COMPETITIVE LANDSCAPE

• 7.1. Introduction
• 7.2. Top Winning Strategies
• 7.3. Product Mapping of Top 10 Player
• 7.4. Competitive Dashboard
• 7.5. Competitive Heatmap
• 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

• 8.1. AbbVie Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Key Executives
  • 8.1.3. Company Snapshot
  • 8.1.4. Operating Business Segments
  • 8.1.5. Product Portfolio
  • 8.1.6. Business Performance
  • 8.1.7. Key Strategic Moves and Developments
• 8.2. Amgen
  • 8.2.1. Company Overview
  • 8.2.2. Key Executives
  • 8.2.3. Company Snapshot
  • 8.2.4. Operating Business Segments
  • 8.2.5. Product Portfolio
  • 8.2.6. Business Performance
  • 8.2.7. Key Strategic Moves and Developments
• 8.3. Astellas Pharma Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Key Executives
  • 8.3.3. Company Snapshot
  • 8.3.4. Operating Business Segments
  • 8.3.5. Product Portfolio
  • 8.3.6. Business Performance
  • 8.3.7. Key Strategic Moves and Developments
• 8.4. AstraZeneca Plc
  • 8.4.1. Company Overview
  • 8.4.2. Key Executives
  • 8.4.3. Company Snapshot
  • 8.4.4. Operating Business Segments
  • 8.4.5. Product Portfolio
  • 8.4.6. Business Performance
  • 8.4.7. Key Strategic Moves and Developments
• 8.5. Bristol-Myers Squibb Company
  • 8.5.1. Company Overview
  • 8.5.2. Key Executives
  • 8.5.3. Company Snapshot
  • 8.5.4. Operating Business Segments
  • 8.5.5. Product Portfolio
  • 8.5.6. Business Performance
  • 8.5.7. Key Strategic Moves and Developments
• 8.6. F. Hoffmann-La Roche Ltd.
  • 8.6.1. Company Overview
  • 8.6.2. Key Executives
  • 8.6.3. Company Snapshot
  • 8.6.4. Operating Business Segments
  • 8.6.5. Product Portfolio
  • 8.6.6. Business Performance
  • 8.6.7. Key Strategic Moves and Developments
• 8.7. Johnson And Johnson
  • 8.7.1. Company Overview
  • 8.7.2. Key Executives
  • 8.7.3. Company Snapshot
  • 8.7.4. Operating Business Segments
  • 8.7.5. Product Portfolio
  • 8.7.6. Business Performance
  • 8.7.7. Key Strategic Moves and Developments
• 8.8. Merck And Co., Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Key Executives
  • 8.8.3. Company Snapshot
  • 8.8.4. Operating Business Segments
  • 8.8.5. Product Portfolio
  • 8.8.6. Business Performance
  • 8.8.7. Key Strategic Moves and Developments
• 8.9. Novartis AG
  • 8.9.1. Company Overview
  • 8.9.2. Key Executives
  • 8.9.3. Company Snapshot
  • 8.9.4. Operating Business Segments
  • 8.9.5. Product Portfolio
  • 8.9.6. Business Performance
  • 8.9.7. Key Strategic Moves and Developments
• 8.10. Pfizer Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Key Executives
  • 8.10.3. Company Snapshot
  • 8.10.4. Operating Business Segments
  • 8.10.5. Product Portfolio
  • 8.10.6. Business Performance
  • 8.10.7. Key Strategic Moves and Developments

관련자료